The C-WORTHY study is a phase 2 , multicentre , randomised controlled trial of grazoprevir plus elbasvir with or without ribavirin in patients with HCV ; here , we report findings for previously untreated ( genotype 1 ) patients without cirrhosis who were HCV mono-infected or HIV/HCV co-infected .